What Is the Science Behind Ozempic, Mounjaro, and Retatrutide? A Beginner’s Guide to Incretin Weight-Loss Drugs, Metabolic Health, and “Biological Age” (Benefits and Risks)

What Are Incretin Weight-Loss Drugs?

“Incretins” are gut hormones released after you eat. They help coordinate metabolism by telling the pancreas, brain, and digestive system what to do next. Two of the most important incretins are GLP-1 and GIP.

Medications in this category mimic (or amplify) these signals to:

• reduce appetite and cravings by acting on brain pathways

• slow stomach emptying, increasing fullness

• improve blood sugar control by boosting insulin when needed and lowering glucagon at the right times

Ozempic vs. Mounjaro: What’s the Difference?

Ozempic is semaglutide, a GLP-1 receptor agonist. It’s FDA-approved for type 2 diabetes, and it also has a cardiovascular risk-reduction indication in certain people with diabetes. Many people lose weight on it, but weight loss is not its main on-label purpose.

Mounjaro is tirzepatide, which acts on two receptors (GIP + GLP-1). Think of it as a “dual-incretin” approach. In obesity trials (marketed as Zepbound for chronic weight management), tirzepatide has produced, on average, greater weight loss than earlier GLP-1–only drugs for many participants—though results vary person to person.

The Evolution Beyond Mounjaro: Why Retatrutide Matters

If Mounjaro is “dual,” the next leap is “triple.”

Retatrutide is an investigational drug that targets GLP-1 + GIP + glucagon. That last hormone—glucagon—usually raises blood sugar, which sounds counterproductive. But in carefully engineered combinations, glucagon signaling may also increase energy expenditure and promote fat oxidation, especially in the liver.

In a major phase 2 obesity trial, retatrutide produced very large average weight loss at higher doses, putting it in the conversation with the most effective options studied so far. Importantly, retatrutide is not FDA-approved, and the FDA has explicitly warned that it is not eligible for compounding and has not been found safe and effective for any condition outside clinical trials.

There are other “branch evolutions,” too—like GLP-1/glucagon co-agonists (for example, mazdutide in phase 2 research)—which reinforce the idea that obesity medicine is moving toward multi-receptor metabolic therapies, not single-hormone tools.

Why Longevity Researchers Are Paying Attention (“Biological Age”)

Metabolic disease and aging share common threads: chronic low-grade inflammation, insulin resistance, and organ stress over time. That’s why incretin drugs are now being evaluated for outcomes beyond the scale—like cardiovascular and kidney protection.

A landmark trial in people with overweight/obesity and established cardiovascular disease (without diabetes) found semaglutide lowered major cardiovascular events. Separately, a kidney outcomes trial in people with type 2 diabetes and chronic kidney disease found semaglutide reduced the risk of serious kidney outcomes and cardiovascular death.

Even more experimental: a post-hoc analysis of a placebo-controlled trial in adults with HIV-associated lipohypertrophy reported that semaglutide shifted several DNA methylation “epigenetic clock” measures in a direction consistent with slower biological aging. This is promising, but it’s early, population-specific evidence—not proof that these drugs “reverse aging” in the general public.

Benefits and Risks to Know

Potential benefits:

• meaningful, sustained weight loss for many patients (especially with newer agents)

• improved blood sugar regulation and insulin sensitivity

• reduced cardiovascular risk in certain high-risk groups

• kidney protection in specific clinical populations

Key risks and trade-offs:

• common GI side effects (nausea, constipation/diarrhea, reflux), especially during dose increases

• rare but serious risks noted in labeling (including gallbladder disease and pancreatitis warnings)

• loss of lean mass can occur with rapid weight loss—making protein intake and resistance training important

• weight regain is common if the medication is stopped, so long-term planning matters

• unapproved or compounded products can pose safety and quality risks

Conclusion

Ozempic (GLP-1) helped launch the modern era of incretin medicine. Mounjaro (GIP + GLP-1) pushed efficacy further. Retatrutide (GLP-1 + GIP + glucagon) represents the next frontier—potentially combining appetite control with higher energy expenditure, but it remains investigational.

If you’re considering any of these therapies, the best “longevity” framing is simple: prioritize medical supervision, protect muscle and nutrition, and treat these medications as powerful metabolic tools—not shortcuts.

Sources:

1. FDA Ozempic (semaglutide) Prescribing Information (label).
2. FDA Mounjaro (tirzepatide) Prescribing Information (label).
3. FDA approval announcement for Zepbound (tirzepatide) for chronic weight management (Nov 8, 2023).
4. Wilding JPH, et al. STEP 1 Trial (semaglutide 2.4 mg) — New England Journal of Medicine (2021).
5. Lincoff AM, et al. SELECT Trial (semaglutide CV outcomes in obesity without diabetes) — New England Journal of Medicine (2023)
6. Perkovic V, et al. FLOW Trial (semaglutide kidney outcomes in T2D with CKD) — New England Journal of Medicine (2024).
7. Jastreboff AM, et al. SURMOUNT-1 Trial (tirzepatide in obesity) — New England Journal of Medicine (2022).
8. Jastreboff AM, et al. Retatrutide phase 2 obesity trial — New England Journal of Medicine (2023).
9. Corley MJ, et al. “Semaglutide Slows Epigenetic Aging in People with HIV-associated lipohypertrophy” — PMC/PubMed (2025).
10. FDA: “Concerns with Unapproved GLP-1 Drugs Used for Weight Loss” (includes retatrutide compounding restrictions) (Feb 4, 2026).
11. STEP 1 body composition (DXA) analysis for semaglutide — PMC (derived from STEP program data).
12. Look M, et al. SURMOUNT-1 body composition (DXA) substudy for tirzepatide — PubMed (2025).